Skip to main content
Top
Published in: Cancer Causes & Control 1/2016

Open Access 01-01-2016 | Original Paper

Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features

Authors: MaryAnn E. VanValkenburg, Gwendolyn I. Pruitt, Ilene K. Brill, Luciano Costa, Maryam Ehtsham, Ian T. Justement, Racquel D. Innis-Shelton, Donna Salzman, E. Shyam P. Reddy, Kelly N. Godby, Fady M. Mikhail, Andrew J. Carroll, Vishnu B. Reddy, Ralph D. Sanderson, Louis B. Justement, Paul W. Sanders, Elizabeth E. Brown

Published in: Cancer Causes & Control | Issue 1/2016

Login to get access

Abstract

Purpose

Multiple myeloma (MM) is the most common hematologic malignancy affecting Blacks in the USA, with standardized incidence rates that are twofold to threefold higher than Whites. The rationale for the disparity is unclear.

Methods

Using participants enrolled in the Molecular And Genetic Epidemiology study of myeloma (259 MM cases; 461 controls), we examined the risk of MM associated with family history of cancer, differences by race and among cases, defining clinical features. Risk estimates were calculated using odds ratios and corresponding 95% confidence intervals from logistic regression adjusted for confounders.

Results

Overall, MM risk in cases with relatives affected with any hematologic malignancy was significantly elevated compared to controls (OR 1.89, 95% CI 1.25–2.86). Myeloma risk associated with a family history of MM was higher than the risk associated with any hematologic malignancy (OR 3.75, 95% CI 1.75–8.05), and the effect was greater for Blacks (OR 20.9, 95% CI 2.59–168) than Whites (OR 2.04, 95% 0.83–5.04), among cases with early onset (≤60 years; OR 4.58, 95% CI 1.21–17.3) and with increasing numbers of affected relatives (p trend = 0.001). Overall, frequencies of end organ damage differed in cases with relatives affected with any hematologic malignancy and significantly more cases exhibited κ light chain restriction (OR 3.23, 95% CI 1.13–9.26).

Conclusions

The excess risk of MM observed in Blacks and the variation in clinical features observed in MM patients according to family history of hematologic malignancy may be attributed to a shared germline and environmental susceptibility.
Appendix
Available only for authorised users
Literature
2.
3.
go back to reference Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417CrossRefPubMedPubMedCentral Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417CrossRefPubMedPubMedCentral
4.
5.
go back to reference Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRefPubMed Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRefPubMed
6.
go back to reference Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366CrossRefPubMedPubMedCentral Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366CrossRefPubMedPubMedCentral
7.
go back to reference Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRefPubMedPubMedCentral Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRefPubMedPubMedCentral
8.
go back to reference Landgren O, Katzmann JA, Hsing AW et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473CrossRefPubMed Landgren O, Katzmann JA, Hsing AW et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473CrossRefPubMed
9.
go back to reference Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501–5506CrossRefPubMedPubMedCentral Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501–5506CrossRefPubMedPubMedCentral
10.
go back to reference Horwitz LJ, Levy RN, Rosner F (1985) Multiple myeloma in three siblings. Arch Intern Med 145:1449–1450CrossRefPubMed Horwitz LJ, Levy RN, Rosner F (1985) Multiple myeloma in three siblings. Arch Intern Med 145:1449–1450CrossRefPubMed
12.
go back to reference Lynch HT, Watson P, Tarantolo S et al (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693CrossRefPubMed Lynch HT, Watson P, Tarantolo S et al (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693CrossRefPubMed
13.
go back to reference Roddie PH, Dang R, Parker AC (1998) Multiple myeloma in three siblings. Clin Lab Haematol 20:191–193CrossRefPubMed Roddie PH, Dang R, Parker AC (1998) Multiple myeloma in three siblings. Clin Lab Haematol 20:191–193CrossRefPubMed
14.
go back to reference Grosbois B, Jego P, Attal M et al (1999) Familial multiple myeloma: report of fifteen families. Br J Haematol 105:768–770CrossRefPubMed Grosbois B, Jego P, Attal M et al (1999) Familial multiple myeloma: report of fifteen families. Br J Haematol 105:768–770CrossRefPubMed
15.
go back to reference Hemminki K, Li X, Czene K (2004) Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108:109–114CrossRefPubMed Hemminki K, Li X, Czene K (2004) Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108:109–114CrossRefPubMed
16.
go back to reference Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ (1985) Multiple myeloma and family history of cancer a case–control study. Cancer 56:2133–2139CrossRefPubMed Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ (1985) Multiple myeloma and family history of cancer a case–control study. Cancer 56:2133–2139CrossRefPubMed
17.
go back to reference Eriksson M, Hållberg B (1992) Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 3:63–67CrossRefPubMed Eriksson M, Hållberg B (1992) Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 3:63–67CrossRefPubMed
18.
go back to reference Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42:1661–1670CrossRefPubMed Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42:1661–1670CrossRefPubMed
19.
go back to reference Kristinsson SY, Björkholm M, Goldin LR et al (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150CrossRefPubMedPubMedCentral Kristinsson SY, Björkholm M, Goldin LR et al (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150CrossRefPubMedPubMedCentral
20.
go back to reference Brown LM, Linet MS, Greenberg RS et al (1999) Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 85:2385–2390CrossRefPubMed Brown LM, Linet MS, Greenberg RS et al (1999) Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 85:2385–2390CrossRefPubMed
21.
go back to reference Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548CrossRefPubMed Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548CrossRefPubMed
22.
go back to reference Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420CrossRefPubMed Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420CrossRefPubMed
23.
go back to reference Howard VJ, Cushman M, Pulley L et al (2005) The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25:135–143CrossRefPubMed Howard VJ, Cushman M, Pulley L et al (2005) The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25:135–143CrossRefPubMed
24.
go back to reference Simpson NK, Johnson CC, Ogden SL et al (2000) Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: the first six years. Control Clin Trials 21:356S–378SCrossRefPubMed Simpson NK, Johnson CC, Ogden SL et al (2000) Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: the first six years. Control Clin Trials 21:356S–378SCrossRefPubMed
25.
go back to reference Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68CrossRefPubMed Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68CrossRefPubMed
26.
27.
go back to reference Altieri A, Bermejo JL, Hemminki K (2005) Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 106:668–672CrossRefPubMed Altieri A, Bermejo JL, Hemminki K (2005) Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 106:668–672CrossRefPubMed
28.
go back to reference Wang SS, Slager SL, Brennan P et al (2006) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the InterLymph Consortium. Blood 109:3479–3488CrossRefPubMed Wang SS, Slager SL, Brennan P et al (2006) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the InterLymph Consortium. Blood 109:3479–3488CrossRefPubMed
29.
go back to reference Broderick P, Chubb D, Johnson DC et al (2012) Common variation at 3p22. 1 and 7p15. 3 influences multiple myeloma risk. Nat Genet 44:58–61CrossRef Broderick P, Chubb D, Johnson DC et al (2012) Common variation at 3p22. 1 and 7p15. 3 influences multiple myeloma risk. Nat Genet 44:58–61CrossRef
30.
go back to reference Chubb D, Weinhold N, Broderick P et al (2013) Common variation at 3q26. 2, 6p21. 33, 17p11. 2 and 22q13. 1 influences multiple myeloma risk. Nat Genet 45:1221–1225CrossRefPubMed Chubb D, Weinhold N, Broderick P et al (2013) Common variation at 3q26. 2, 6p21. 33, 17p11. 2 and 22q13. 1 influences multiple myeloma risk. Nat Genet 45:1221–1225CrossRefPubMed
31.
go back to reference Weinhold N, Johnson DC, Chubb D et al (2013) The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 45:522–525CrossRefPubMed Weinhold N, Johnson DC, Chubb D et al (2013) The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 45:522–525CrossRefPubMed
32.
go back to reference Pottern LM, Gart JJ, Nam JM et al (1992) HLA and multiple myeloma among black and white men: evidence of a genetic association. CEBP 1:177–182 Pottern LM, Gart JJ, Nam JM et al (1992) HLA and multiple myeloma among black and white men: evidence of a genetic association. CEBP 1:177–182
33.
go back to reference Schoenfeld Y, Berliner S, Shaklai M, Gallant LA, Pinkhas J (1982) Familial multiple myeloma. A review of 37 families. Postgrad Med J 58:12–16CrossRef Schoenfeld Y, Berliner S, Shaklai M, Gallant LA, Pinkhas J (1982) Familial multiple myeloma. A review of 37 families. Postgrad Med J 58:12–16CrossRef
34.
go back to reference Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRefPubMedPubMedCentral Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRefPubMedPubMedCentral
35.
go back to reference Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59CrossRefPubMedPubMedCentral Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59CrossRefPubMedPubMedCentral
36.
go back to reference Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case–control study. Int J Cancer 118:3095–3098CrossRefPubMed Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case–control study. Int J Cancer 118:3095–3098CrossRefPubMed
37.
go back to reference Lindqvist EK, Goldin LR, Landgren O et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRefPubMedPubMedCentral Lindqvist EK, Goldin LR, Landgren O et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRefPubMedPubMedCentral
38.
go back to reference McShane CM, Murray LJ, Landgren O et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. CEBP 23:332–342 McShane CM, Murray LJ, Landgren O et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. CEBP 23:332–342
39.
40.
go back to reference Bjornsson HT, Cui H, Gius D, Fallin MD, Feinberg AP (2004) The new field of epigenomics: implications for cancer and other common disease research. Cold Spring Harb Symp Quant Biol 69:447–456CrossRefPubMed Bjornsson HT, Cui H, Gius D, Fallin MD, Feinberg AP (2004) The new field of epigenomics: implications for cancer and other common disease research. Cold Spring Harb Symp Quant Biol 69:447–456CrossRefPubMed
41.
go back to reference Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. Trends Genet 20:350–358CrossRefPubMed Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. Trends Genet 20:350–358CrossRefPubMed
42.
go back to reference Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440CrossRefPubMed Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440CrossRefPubMed
Metadata
Title
Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features
Authors
MaryAnn E. VanValkenburg
Gwendolyn I. Pruitt
Ilene K. Brill
Luciano Costa
Maryam Ehtsham
Ian T. Justement
Racquel D. Innis-Shelton
Donna Salzman
E. Shyam P. Reddy
Kelly N. Godby
Fady M. Mikhail
Andrew J. Carroll
Vishnu B. Reddy
Ralph D. Sanderson
Louis B. Justement
Paul W. Sanders
Elizabeth E. Brown
Publication date
01-01-2016
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 1/2016
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-015-0685-2

Other articles of this Issue 1/2016

Cancer Causes & Control 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine